drugset / Trial / NCT06283134
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
Phase 1
Not yet recruiting
60 enrolled
China Medical University, China
Beijing Bio-Targeting Therapeutics Technology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label clinical study of BioTTT001 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
Timeline
- Start
- 2026-03
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BioTTT001 | Unknown | 5e+09 vg | Other |
| Subject | BioTTT001 | Unknown | 5e+10 vg | Other |
| Subject | BioTTT001 | Unknown | 1e+11 vg | Other |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 160 mg | Intravenous |